Amicus Therapeutics, Inc. (FOLD)

Over the past six months, Amicus Therapeutics' stock has experienced significant events, including BioMarin Pharmaceutical Inc.'s intention to acquire Amicus Therapeutics for $4.8 billion. In the third quarter of 2024, Amicus Therapeutics reported strong performance, exceeding expectations with total revenue reaching $142 million, a 37% year-over-year growth. A key intellectual property settlement with Teva Pharmaceuticals allows for a generic version of Galafold in the U.S. starting January 30, 2037. Jefferies downgraded Amicus Therapeutics to "Buy" and lowered its price target amid takeover developments. Halper Sadeh LLC initiated an investigation into whether the sale of Amicus Therapeutics, Inc. is fair to shareholders. Insider selling activity by CEO Bradley Campbell and other executives was also reported in late 2025 and early 2026.

There is no direct information available regarding demand seasonality for Amicus Therapeutics' specific products or services.

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering novel medicines for people living with rare diseases, particularly lysosomal storage disorders. The company's major commercial products include Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. Amicus Therapeutics also has a rare disease gene therapy portfolio.

Amicus Therapeutics has a significant market presence in the United States and internationally. The company has seen strong commercial demand in the U.S. and several European countries, including Italy, Switzerland, Portugal, the Czech Republic, Sweden, and the Netherlands. Amicus Therapeutics also anticipates launching its products in additional countries, including Japan.

Amicus Therapeutics maintains a reputation as a patient-dedicated biotechnology company committed to developing and delivering transformative medicines for rare diseases. The company emphasizes scientific rigor, patient advocacy, and a strong patient-centric focus. The announced acquisition by BioMarin Pharmaceutical Inc. for $4.8 billion in December 2025 can be seen as a positive reflection of Amicus's assets and potential. There is no explicit information indicating negative events that have significantly impacted Amicus Therapeutics' brand reputation in the past year, beyond the standard scrutiny that comes with a major acquisition.

Amicus Therapeutics (FOLD) stock ownership is a mix of institutional, insider, and public/individual investors. Approximately 56.32% to 75.96% of the company's stock is owned by institutional investors, 1.03% by insiders, and 19.63% to 23.01% by public companies and individual investors. Major institutional owners include Vanguard Group Inc., Wellington Management Group Llp, BlackRock, Inc., William Blair Investment Management, Llc, Avoro Capital Advisors LLC, Millennium Management Llc, State Street Corp, and Vestal Point Capital, LP. Perceptive Advisors LLC is noted as a significant individual shareholder.